{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6920ca6bc367efee96351efb/6ad9567e5de627c54068c127?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Have we been thinking about GLP-1s all wrong? with Dr. Melanie Dewar","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6920ca6bc367efee96351efb/1792627112372-30c7e2b0-e22e-468f-b22e-8c5146ec45e6.jpeg?height=200","description":"<p>When most of us hear GLP-1, we immediately think of Ozempic, Wegovy, weight loss, and all the controversy surrounding these medications.</p><p>But what if weight loss is only part of the story?</p><p>There&#39;s growing research into what these drugs might mean for everything from heart health and inflammation to sleep apnea, addiction, and even Alzheimer&#39;s.</p><p>So are we looking at something that could fundamentally change how we approach health and aging? Or are we getting a little ahead of the science?</p><p>Today we&#39;re joined by Dr. Melanie Dewar to help us separate the facts from the hype and explore what these medications may—and may not—be able to do.</p>","author_name":"Susan Feldman and Phyllis Berger"}